World’s First AI-Designed Vaccine Tested in Humans by Cambridge 2026

Key Points

• The University of Cambridge has conducted the world’s first human clinical trial of a vaccine whose key antigen was designed entirely by artificial intelligence.
• The DNA vaccine targets sarbecoviruses a group of coronaviruses including SARS-CoV-2 (COVID-19) and SARS plus related bat viruses that could cause future pandemics.
• 39 healthy volunteers aged 18–50 received the vaccine at two UK medical sites in Southampton and Cambridge.
• The trial reported no significant side effects; the vaccine was “safe and well tolerated”.
• The AI-designed antigen triggered a protective immune response, producing antibodies that recognise multiple sarbecoviruses.
• Because of its AI-driven design approach, the vaccine may also protect against diseases that have not yet emerged.
• The research was carried out by Cambridge researchers alongside spin-out company DIOSynVax (DVX) Ltd.
• Results were published in early June 2026, with multiple outlets reporting the trial’s success on 4–8 June 2026.
• This is described as “the first instance of a vaccine antigen designed exclusively by artificial intelligence” used in human trials.
• The technology is seen as a potential step toward a “universal vaccine” to prevent future pandemics before they take hold.

Cambridge (Cambridge Tribune) June 13, 2026 — The University of Cambridge has run the world’s first human trial of a vaccine designed entirely by artificial intelligence, targeting sarbecoviruses including SARS-CoV-2 and SARS, with no significant side effects reported and a protective immune response demonstrated in 39 healthy volunteers.

As reported by the engAdet team on 4 June 2026, this is “the first instance of a vaccine antigen designed exclusively by artificial intelligence” used in humans, marking a historic shift in how medical vaccines can be created.

According to Gavi’s “Vaccines Work” blog published 8 June 2026, researchers describe this as “a fundamentally new type of vaccine using artificial intelligence,” where the vaccine’s key component was designed entirely by AI and tested in people for the first time.

Medical Xpress reported on 6 June 2026 that the trial, developed by Cambridge and spin-out DIOSynVax (DVX) Ltd, showed the vaccine is safe and has no significant side effects, clearing the first human clinical trial for a universal Sarbeco coronavirus vaccine.

How Was the AI-Designed Vaccine Tested in Humans?

As reported by engAdet, the vaccine was given to 39 healthy volunteers between the ages of 18 and 50 at two UK medical facilities located in Southampton and Cambridge.

The trial focused on a DNA vaccine whose active ingredient — the antigen — was created entirely by AI, not by traditional laboratory methods.

According to Gavi, the results showed that this DNA vaccine stimulated the immune system to produce antibodies that can recognise different types of sarbecoviruses.

The technology was found to be safe and well tolerated, with no significant side effects reported among participants.

Which Viruses Does the AI Vaccine Target?

As reported by engAdet, the vaccine was designed to protect people against a number of Sarbeco coronaviruses, a group that includes:

• SARS-CoV-2, responsible for the global COVID pandemic in 2020
• SARS, the virus that caused the 2002–2004 SARS outbreak
• Related bat viruses that could cause pandemics in the future

Gavi confirms that the AI-designed antigen triggered a protective immune response against SARS-CoV-2 and SARS, as well as related bat viruses.

Because of the way the vaccine was developed using AI, it will likely also provide protection against diseases that haven’t even emerged yet, according to Cambridge researchers cited by engAdet.

What Do the Trial Results Show About Safety and Immune Response?

As reported by Medical Xpress on 6 June 2026, the first human clinical trial of the universal Sarbeco coronavirus vaccine showed that the vaccine is safe and has no significant side effects.

Gavi states that the technology was “safe and well tolerated” in all participants.

The AI-designed antigen triggered a protective immune response in volunteers, producing antibodies that can recognise multiple sarbecoviruses, not just a single virus.

This cross-recognition is critical for a “universal” vaccine approach, as it means the shot could work against several related coronaviruses, including future variants or new strains.

Why Is This the First AI-Designed Vaccine Trial in Humans?

As reported by engAdet, this is the first time that a vaccine with an active component designed entirely by a computer has been used in human trials.

Gavi confirms: 

“This is the first human trial of an AI-designed vaccine”.

Previous vaccine development has relied on laboratory-based methods, animal testing, and human-guided design. In this trial, artificial intelligence alone designed the key antigen, representing a fundamentally new approach to vaccine creation.

The University of Cambridge team utilised AI technology to create what they call a universal vaccine that could be used to prevent future pandemics before they take hold.

Who Led the Research and Which Companies Were Involved?

The research was carried out by researchers from the University of Cambridge, working alongside spin-out company DIOSynVax (DVX) Ltd, as reported by Medical Xpress.

DIOSynVax is a Cambridge-based biotech company focused on using AI and computational design to create next-generation vaccines against emerging infectious diseases.

The collaboration between Cambridge and DIOSynVax demonstrates how academic research and private biotech can combine to accelerate AI-driven medical innovation.

What Background Explains the Development of This AI-Designed Vaccine?

The AI-designed vaccine stems from growing interest in using artificial intelligence to accelerate and redesign vaccine development. Traditional vaccine creation often takes years of laboratory work, animal testing, and iterative human design. AI can analyse vast datasets of viral structures, predict which antigens will trigger strong immune responses, and design them computationally before any physical testing begins.

Cambridge researchers have been working on universal coronavirus vaccines that target not just SARS-CoV-2 but entire groups of related viruses. The sarbecovirus group includes multiple coronaviruses found in bats that could jump to humans. By targeting this group, the vaccine aims to provide broad protection against current and future threats.

The development of DIOSynVax (DVX) Ltd as a Cambridge spin-out highlights the university’s role in translating AI research into real-world medical products. The company’s focus on computational vaccine design aligns with global efforts to prepare for future pandemics.

This trial is part of a broader trend in AI-driven medicine, where machine learning models are used to design drugs, predict protein structures, and optimise treatment strategies. The successful human trial of an AI-designed antigen is a milestone that could encourage more investment and research in this area.

How Will This AI Vaccine Development Affect Patients, Scientists, and the Public?

For Patients and the General Public

This development could reduce the time needed to respond to future pandemics. If AI can design vaccine antigens quickly, health authorities may be able to deploy protective shots before a virus spreads widely.

A vaccine that protects against multiple sarbecoviruses, including future bat viruses, could provide long-term security against coronavirus families that have not yet caused outbreaks. This may lower fear and uncertainty about unknown viruses.

If the vaccine proves effective in larger trials, it could become part of routine vaccination programmes, especially for high-risk groups or people in regions with frequent virus exposure.

For Scientists and Vaccine Developers

This trial validates AI as a credible tool for vaccine antigen design, opening the door for more AI-designed vaccines against other virus families.

Researchers may now focus on expanding AI-designed vaccines to other pathogens, such as influenza, HIV, or emerging viruses beyond coronaviruses.

The success could lead to increased funding and partnerships between universities, biotech companies, and governments to develop AI-driven vaccine platforms.

For Governments and Health Authorities

Governments may see AI vaccine design as a strategic advantage for pandemic preparedness, potentially investing in national AI vaccine labs.

Health organisations like the WHO could incorporate AI-designed vaccines into global pandemic response plans, speeding up international vaccine distribution.

The trial’s success may encourage regulatory bodies to create new frameworks for evaluating AI-designed medical products, ensuring safety while enabling innovation.